Page last updated: 2024-10-19

2,3,4,5-tetrahydroxypentanal and Kidney Diseases

2,3,4,5-tetrahydroxypentanal has been researched along with Kidney Diseases in 2 studies

Kidney Diseases: Pathological processes of the KIDNEY or its component tissues.

Research Excerpts

ExcerptRelevanceReference
"Regarding cancer, MCP modulates several rate-limiting steps of the metastatic cascade."2.61Pleiotropic Effects of Modified Citrus Pectin. ( Eliaz, I; Raz, A, 2019)

Research

Studies (2)

TimeframeStudies, this research(%)All Research%
pre-19900 (0.00)18.7374
1990's0 (0.00)18.2507
2000's0 (0.00)29.6817
2010's2 (100.00)24.3611
2020's0 (0.00)2.80

Authors

AuthorsStudies
Eliaz, I1
Raz, A1
Martínez-Martínez, E1
Ibarrola, J1
Fernández-Celis, A1
Calvier, L1
Leroy, C1
Cachofeiro, V1
Rossignol, P1
López-Andrés, N1

Reviews

1 review available for 2,3,4,5-tetrahydroxypentanal and Kidney Diseases

ArticleYear
Pleiotropic Effects of Modified Citrus Pectin.
    Nutrients, 2019, Nov-01, Volume: 11, Issue:11

    Topics: Adipose Tissue; Aortic Valve Stenosis; Blood Proteins; Citrus; Fibrosis; Galectin 3; Galectins; Huma

2019

Other Studies

1 other study available for 2,3,4,5-tetrahydroxypentanal and Kidney Diseases

ArticleYear
Galectin-3 pharmacological inhibition attenuates early renal damage in spontaneously hypertensive rats.
    Journal of hypertension, 2018, Volume: 36, Issue:2

    Topics: Actins; Acute Kidney Injury; Acute-Phase Proteins; Albuminuria; Animals; Antigens, CD; beta Catenin;

2018